SCHEMBL6673429

SCHEMBL6673429

COc1cc(OC)cc(N2CCN(C(=NO)Nc3cc(C(C)=NO)c(C)nc3OC)CC2)c1

nearest known ligand 0.42

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PHGDH O43175 5/20 0.42
CYP3A4 P08684 4/20 0.39
CYP2C19 P33261 2/20 0.39
HSD17B10 Q99714 1/20 0.37
L3MBTL1 Q9Y468 2/20 0.35
KMT2A Q03164 6/20 0.33
MEN1 O00255 4/20 0.33
MAPK1 P28482 2/20 0.33
FGFR4 P22455 1/20 0.33
PKM P14618 1/20 0.33
ADRB1 P08588 1/20 0.33
LMNA P02545 1/20 0.33
GFER P55789 1/20 0.33
CYP2C9 P11712 2/20 0.33
POLB P06746 2/20 0.33
ALDH1A1 P00352 1/20 0.33
MAPT P10636 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6675916 0.91 PHGDH (0.42) PHGDHCYP3A4CYP2C19HSD17B10L3MBTL1
SCHEMBL6677879 0.91 PHGDH (0.38) PHGDHCYP3A4CYP2C19HSD17B10KMT2A
SCHEMBL6672611 0.89 CYP3A4 (0.32) PHGDHCYP3A4CYP2C19HSD17B10LMNA
SCHEMBL6679165 0.89 KMT2A (0.42) PHGDHCYP3A4CYP2C19HSD17B10L3MBTL1
SCHEMBL6672614 0.88 PHGDH (0.45) PHGDHCYP3A4CYP2C19HSD17B10L3MBTL1
SCHEMBL6673720 0.85 MAPT (0.35) KMT2AMEN1MAPK1LMNAPOLB
SCHEMBL6676875 0.84 PHGDH (0.42) PHGDHCYP3A4CYP2C19HSD17B10L3MBTL1
SCHEMBL6678312 0.84 PHGDH (0.42) PHGDHCYP3A4CYP2C19HSD17B10L3MBTL1
SCHEMBL6674803 0.83 PHGDH (0.42) PHGDHCYP3A4CYP2C19HSD17B10L3MBTL1
SCHEMBL6673426 0.83 PHGDH (0.39) PHGDHCYP3A4CYP2C19HSD17B10L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1424072-A1 N'-(pyridin-3-yl)-(4-phenylpiperazin-1-yl)-carboxyimidamide and -iminothiolate derivatives for the treatment of tumors Samjin Pharmaceutical Co., Ltd. (KR) 2004-06-02 EP disclosed
US-6683184-B2 ANTITUMOR AGENTS SAMJIN PHARMACEUTICAL CO., LTD. (KR) 2004-01-27 US disclosed
US-20030092910-A1 Piperazine derivatives and process for the preparation thereof SAMJIN PHARMACEUTICAL CO., LTD. (KR) 2003-05-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030092910-A1 Piperazine derivatives and process for the preparation thereof CBR1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HCCS PHGDH 2923/4885CYP3A4 339/4885CYP2C19 1186/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.